<p>Accolade, Inc. (纳斯达克股票代码: ACCD) 被目前覆盖该公司的十五家经纪公司给予了&#34;中等买入&#34;的平均推荐评级，Marketbeat.com 报告称。三位股票研究分析师对该股票给予持有评级，而十二位则给予该公司买入评级。过去一年内对该股票发表评级的分析师中，平均 12 个月的目标股价为 11.65 美元。</p>
<p>ACCD 最近成为多份研究报告的讨论话题。富国银行公司将 Accolade 的目标股价从 12.00 美元下调至 10.00 美元，并在 4 月 30 日的一份研究报告中给予该股票&#34;持平&#34;评级。Truist Financial 将 Accolade 的价格目标从 14.00 美元下调至 9.00 美元，并在 6 月 28 日星期五的一份研究报告中给予该股票&#34;买入&#34;评级。Stifel Nicolaus 将 Accolade 的价格目标从 13.00 美元下调至 8.00 美元，并在 6 月 28 日星期五的一份研究报告中给予该股票&#34;买入&#34;评级。巴克莱将 Accolade 的价格目标从 11.00 美元下调至 5.50 美元，并在 6 月 28 日星期五的一份研究报告中给予该股票&#34;持平&#34;评级。最后，摩根大通将 Accolade 的价格目标从 12.00 美元下调至 6.00 美元，并在 6 月 28 日星期五的一份研究报告中给予该股票&#34;持平&#34;评级。</p>
<p><strong>查看我们关于 Accolade 的最新股票报告</strong></p>
<h2>Accolade 股票表现</h2>
<ul>
<li>Accolade：崛起的个性化人工智能健康平台</li>
</ul>
<p>ACCD 股票周五开盘价为 3.52 美元。该公司的市值为 2.8163 亿美元，市盈率为-3.03，贝塔系数为 2.00。公司的速动比率为 2.80，流动比率为 2.80，负债权益比为 0.48。该企业的 50 天移动平均价格为 4.77 美元，200 天移动平均价格为 7.98 美元。Accolade 的 12 个月最低价为 3.35 美元，最高价为 15.36 美元。</p>
<p>Accolade (纳斯达克股票代码: ACCD) 上次公布季度财报是在 6 月 27 日星期四。公司报告该季度每股亏损为 0.35 美元，超过了每股亏损 0.13 美元的共识预期。Accolade 的净资产回报率为-20.30%，净利润率为-20.62%。该季度营收为 1.105 亿美元，超过了 1.0522 亿美元的共识预期。与去年同期相比，Accolade 的季度营收同比增长了 18.6%。卖方分析师预计，Accolade 今年将实现每股-1.17 美元的盈利。</p>
<h2>Accolade 内部交易</h2>
<ul>
<li>Accolade 股价上涨，但增长放缓</li>
</ul>
<p>在其他 Accolade 新闻中，首席会计官 Colin Mchugh 在 6 月 12 日星期三的一笔交易中出售了 5,543 股 Accolade 股票。这些股票的平均价格为 6.62 美元，总价值为 36,694.66 美元。交易完成后，首席会计官现在持有该公司股票的 50,177 股，价值 332,171.74 美元。该交易已在提交给证券交易委员会的文件中披露，可以通过此链接访问。在过去的九十天里，内部人士出售了价值 106,760 美元的公司股票 19,539 股。公司内部人士持有公司股份的比例为 8.20%。</p>
<h2>机构投资者对 Accolade 的看法</h2>
<p>一些大型投资者最近调整了他们对 ACCD 的持股。瑞士国家银行在第一季度将其持有的 Accolade 股份增加了 1.7%。瑞士国家银行现在持有该公司股票的 137,500 股，价值 1,441,000 美元，比上一季度增加了 2,300 股。Price T Rowe Associates Inc. MD 在第一季度将其对 Accolade 的持股增加了 15.3%。Price T Rowe Associates Inc. MD 现在持有该公司股票的 19,540 股，价值 205,000 美元，比上一季度增加了 2,586 股。苏黎世州立银行在第二季度将其对 Accolade 的持股增加了 22.8%。苏黎世州立银行现在持有该公司股票的 20,373 股，价值 73,000 美元，比上一季度增加了 3,789 股。苏黎世州立银行在第四季度将其对 Accolade 的持股增加了 39.0%。苏黎世州立银行现在持有该公司股票的 16,584 股，价值 199,000 美元，比上一季度增加了 4,656 股。最后，AJOVista LLC 在第四季度购入了一笔新的 Accolade 股份，价值约 68,000 美元。84.99% 的股份由对冲基金和其他机构投资者持有。</p>
<h2>关于 Accolade（获取免费报告</h2>
<p>Accolade, Inc. 及其子公司致力于开发和提供个性化和技术支持解决方案，帮助人们了解、导航和利用美国的医疗保健系统和工作场所福利。该公司提供一种平台，采用基于云的技术，并得到健康助理和临床医生团队的多模式支持，包括注册护士、医师医学主任、药剂师、行为健康专家、妇女健康专家、病例管理专家、专家医学意见提供者和虚拟初级保健医生。</p>
<h2>推荐故事</h2>
<ul>
<li>我们喜欢的五只股票胜过 Accolade</li>
<li>投资者必须了解场外交易（OTC）股票</li>
<li>大麻行业：盈利能力成为焦点</li>
<li>什么是股息挑战者？</li>
<li>亚马逊股价暴跌：是一个主要的买入机会吗？</li>
<li>盈利交易 52 周高位股票</li>
<li>在 e.l.f. Beauty 的低点买入</li>
</ul>
<p><em>这则即时新闻警报是由叙事科技和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快速和最准确的报道。在发布之前，该故事经过了 MarketBeat 编辑团队的审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<p>→ 华尔街传奇：降息无法阻止未来发展（来自 Stansberry Research）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTMz?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTMz"/></p>
<h2>现在是否值得投资 1000 美元购买 Accolade 股票？</h2>
<p>在考虑购买 Accolade 股票之前，您需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街评级最高、表现最佳的研究分析师以及他们向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在应该购买的股票，而 Accolade 不在这个名单上。</p>
<p>虽然 Accolade 目前在分析师中拥有 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

ACCD

<p>Accolade, Inc.（纳斯达克股票代码：ACCD）收到了来自券商的 “中等买入” 平均推荐。分析师给出了该股票的 12 个月价格目标为$11.65。该公司的市值为$2.8163 亿美元，12 个月最高价为$15.36。Accolade 报告称季度盈利为正，超过了预期。内部人士已经出售了公司股票，而大型机构投资者已调整了其持股</p>

<p>Accolade, Inc. (NASDAQ:ACCD - Get Free Report) has been given an average recommendation of &#34;Moderate Buy&#34; by the fifteen brokerages that are currently covering the firm, Marketbeat.com reports. Three equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $11.65.</p>
<ul>
<li>MarketBeat Week in Review – 7/10 - 7/14</li>
</ul>
<div class="lb-trans"><p>Accolade, Inc. (纳斯达克股票代码: ACCD) 被目前覆盖该公司的十五家经纪公司给予了&#34;中等买入&#34;的平均推荐评级，Marketbeat.com 报告称。三位股票研究分析师对该股票给予持有评级，而十二位则给予该公司买入评级。过去一年内对该股票发表评级的分析师中，平均 12 个月的目标股价为 11.65 美元。</p>
</div><p>ACCD has been the topic of several recent research reports. Wells Fargo &amp; Company dropped their target price on Accolade from $12.00 to $10.00 and set an &#34;equal weight&#34; rating on the stock in a research report on Tuesday, April 30th. Truist Financial lowered their price objective on Accolade from $14.00 to $9.00 and set a &#34;buy&#34; rating on the stock in a research report on Friday, June 28th. Stifel Nicolaus lowered their price objective on Accolade from $13.00 to $8.00 and set a &#34;buy&#34; rating on the stock in a research report on Friday, June 28th. Barclays lowered their price objective on Accolade from $11.00 to $5.50 and set an &#34;equal weight&#34; rating on the stock in a research report on Friday, June 28th. Finally, Morgan Stanley lowered their price objective on Accolade from $12.00 to $6.00 and set an &#34;equal weight&#34; rating on the stock in a research report on Friday, June 28th.</p>
<div class="lb-trans"><p>ACCD 最近成为多份研究报告的讨论话题。富国银行公司将 Accolade 的目标股价从 12.00 美元下调至 10.00 美元，并在 4 月 30 日的一份研究报告中给予该股票&#34;持平&#34;评级。Truist Financial 将 Accolade 的价格目标从 14.00 美元下调至 9.00 美元，并在 6 月 28 日星期五的一份研究报告中给予该股票&#34;买入&#34;评级。Stifel Nicolaus 将 Accolade 的价格目标从 13.00 美元下调至 8.00 美元，并在 6 月 28 日星期五的一份研究报告中给予该股票&#34;买入&#34;评级。巴克莱将 Accolade 的价格目标从 11.00 美元下调至 5.50 美元，并在 6 月 28 日星期五的一份研究报告中给予该股票&#34;持平&#34;评级。最后，摩根大通将 Accolade 的价格目标从 12.00 美元下调至 6.00 美元，并在 6 月 28 日星期五的一份研究报告中给予该股票&#34;持平&#34;评级。</p>
</div><p><strong>View Our Latest Stock Report on Accolade</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Accolade 的最新股票报告</strong></p>
</div><h2>Accolade Stock Performance</h2>
<ul>
<li>Accolade: A Rising Personalized AI-Powered Healthcare Platform</li>
</ul>
<div class="lb-trans"><h2>Accolade 股票表现</h2>
<ul>
<li>Accolade：崛起的个性化人工智能健康平台</li>
</ul>
</div><p>ACCD stock opened at $3.52 on Friday. The firm has a market cap of $281.63 million, a PE ratio of -3.03 and a beta of 2.00. The company has a quick ratio of 2.80, a current ratio of 2.80 and a debt-to-equity ratio of 0.48. The business has a 50 day moving average of $4.77 and a 200-day moving average of $7.98. Accolade has a 12-month low of $3.35 and a 12-month high of $15.36.</p>
<div class="lb-trans"><p>ACCD 股票周五开盘价为 3.52 美元。该公司的市值为 2.8163 亿美元，市盈率为-3.03，贝塔系数为 2.00。公司的速动比率为 2.80，流动比率为 2.80，负债权益比为 0.48。该企业的 50 天移动平均价格为 4.77 美元，200 天移动平均价格为 7.98 美元。Accolade 的 12 个月最低价为 3.35 美元，最高价为 15.36 美元。</p>
</div><p>Accolade (NASDAQ:ACCD - Get Free Report) last posted its quarterly earnings data on Thursday, June 27th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.13. Accolade had a negative return on equity of 20.30% and a negative net margin of 20.62%. The business had revenue of $110.50 million for the quarter, compared to the consensus estimate of $105.22 million. During the same quarter in the prior year, the business earned ($0.52) earnings per share. Accolade's revenue for the quarter was up 18.6% on a year-over-year basis. As a group, sell-side analysts expect that Accolade will post -1.17 earnings per share for the current year.</p>
<div class="lb-trans"><p>Accolade (纳斯达克股票代码: ACCD) 上次公布季度财报是在 6 月 27 日星期四。公司报告该季度每股亏损为 0.35 美元，超过了每股亏损 0.13 美元的共识预期。Accolade 的净资产回报率为-20.30%，净利润率为-20.62%。该季度营收为 1.105 亿美元，超过了 1.0522 亿美元的共识预期。与去年同期相比，Accolade 的季度营收同比增长了 18.6%。卖方分析师预计，Accolade 今年将实现每股-1.17 美元的盈利。</p>
</div><h2>Insider Transactions at Accolade</h2>
<ul>
<li>Accolade Moves Higher But Growth Is Slowing</li>
</ul>
<div class="lb-trans"><h2>Accolade 内部交易</h2>
<ul>
<li>Accolade 股价上涨，但增长放缓</li>
</ul>
</div><p>In other Accolade news, CAO Colin Mchugh sold 5,543 shares of Accolade stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $6.62, for a total value of $36,694.66. Following the completion of the transaction, the chief accounting officer now owns 50,177 shares of the company's stock, valued at $332,171.74. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this link. Over the last ninety days, insiders sold 19,539 shares of company stock worth $106,760. Company insiders own 8.20% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Accolade 新闻中，首席会计官 Colin Mchugh 在 6 月 12 日星期三的一笔交易中出售了 5,543 股 Accolade 股票。这些股票的平均价格为 6.62 美元，总价值为 36,694.66 美元。交易完成后，首席会计官现在持有该公司股票的 50,177 股，价值 332,171.74 美元。该交易已在提交给证券交易委员会的文件中披露，可以通过此链接访问。在过去的九十天里，内部人士出售了价值 106,760 美元的公司股票 19,539 股。公司内部人士持有公司股份的比例为 8.20%。</p>
</div><h2>Institutional Investors Weigh In On Accolade</h2>
<div class="lb-trans"><h2>机构投资者对 Accolade 的看法</h2>
</div><p>A number of large investors have recently modified their holdings of ACCD. Swiss National Bank increased its holdings in shares of Accolade by 1.7% in the 1st quarter. Swiss National Bank now owns 137,500 shares of the company's stock valued at $1,441,000 after purchasing an additional 2,300 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in Accolade by 15.3% during the first quarter. Price T Rowe Associates Inc. MD now owns 19,540 shares of the company's stock valued at $205,000 after buying an additional 2,586 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in Accolade by 22.8% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 20,373 shares of the company's stock valued at $73,000 after buying an additional 3,789 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Accolade by 39.0% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,584 shares of the company's stock valued at $199,000 after purchasing an additional 4,656 shares during the period. Finally, AJOVista LLC purchased a new stake in shares of Accolade during the fourth quarter valued at approximately $68,000. 84.99% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>一些大型投资者最近调整了他们对 ACCD 的持股。瑞士国家银行在第一季度将其持有的 Accolade 股份增加了 1.7%。瑞士国家银行现在持有该公司股票的 137,500 股，价值 1,441,000 美元，比上一季度增加了 2,300 股。Price T Rowe Associates Inc. MD 在第一季度将其对 Accolade 的持股增加了 15.3%。Price T Rowe Associates Inc. MD 现在持有该公司股票的 19,540 股，价值 205,000 美元，比上一季度增加了 2,586 股。苏黎世州立银行在第二季度将其对 Accolade 的持股增加了 22.8%。苏黎世州立银行现在持有该公司股票的 20,373 股，价值 73,000 美元，比上一季度增加了 3,789 股。苏黎世州立银行在第四季度将其对 Accolade 的持股增加了 39.0%。苏黎世州立银行现在持有该公司股票的 16,584 股，价值 199,000 美元，比上一季度增加了 4,656 股。最后，AJOVista LLC 在第四季度购入了一笔新的 Accolade 股份，价值约 68,000 美元。84.99% 的股份由对冲基金和其他机构投资者持有。</p>
</div><h2>About Accolade (Get Free Report</h2>
<div class="lb-trans"><h2>关于 Accolade（获取免费报告</h2>
</div><p>Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women's health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians.</p>
<div class="lb-trans"><p>Accolade, Inc. 及其子公司致力于开发和提供个性化和技术支持解决方案，帮助人们了解、导航和利用美国的医疗保健系统和工作场所福利。该公司提供一种平台，采用基于云的技术，并得到健康助理和临床医生团队的多模式支持，包括注册护士、医师医学主任、药剂师、行为健康专家、妇女健康专家、病例管理专家、专家医学意见提供者和虚拟初级保健医生。</p>
</div><h2>Recommended Stories</h2>
<ul>
<li>Five stocks we like better than Accolade</li>
<li>What Investors Must Know About Over-the-Counter (OTC) Stocks</li>
<li>The Cannabis Sector: Profitability Takes Center Stage</li>
<li>What Are Dividend Challengers?</li>
<li>Amazon’s Stock Plunge: Is a Prime Buying Opportunity Knocking?</li>
<li>Profitably Trade Stocks at 52-Week Highs</li>
<li>Buy the Dip in e.l.f. Beauty: Analysts Point to a New High</li>
</ul>
<div class="lb-trans"><h2>推荐故事</h2>
<ul>
<li>我们喜欢的五只股票胜过 Accolade</li>
<li>投资者必须了解场外交易（OTC）股票</li>
<li>大麻行业：盈利能力成为焦点</li>
<li>什么是股息挑战者？</li>
<li>亚马逊股价暴跌：是一个主要的买入机会吗？</li>
<li>盈利交易 52 周高位股票</li>
<li>在 e.l.f. Beauty 的低点买入</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUNDRA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=ACCD"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由叙事科技和来自 MarketBeat 的金融数据生成的，旨在为读者提供最快速和最准确的报道。在发布之前，该故事经过了 MarketBeat 编辑团队的审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><p>→ Wall St Legend: Rate Cuts Can't Stop What's Next (From Stansberry Research)(Ad)</p>
<div class="lb-trans"><p>→ 华尔街传奇：降息无法阻止未来发展（来自 Stansberry Research）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTMz" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9133&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Accolade right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资 1000 美元购买 Accolade 股票？</h2>
</div><p>Before you consider Accolade, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑购买 Accolade 股票之前，您需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Accolade wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街评级最高、表现最佳的研究分析师以及他们向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在应该购买的股票，而 Accolade 不在这个名单上。</p>
</div><p>While Accolade currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Accolade 目前在分析师中拥有 “中等买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Accolade, Inc. (NASDAQ:ACCD) 获得券商的 “适度买入” 平均推荐